Finerenone in Persons with Chronic Kidney Disease without Diabetes.
Publication/Presentation Date
8-6-2026
Abstract
BACKGROUND: In randomized trials, finerenone, a nonsteroidal mineralocorticoid receptor antagonist, improved kidney and cardiovascular outcomes in patients with type 2 diabetes and chronic kidney disease (CKD). Whether finerenone has similar effects in patients without diabetes who have CKD is unknown.
METHODS: We randomly assigned adults without diabetes who had CKD (estimated glomerular filtration rate [eGFR], 25 to < 90 ml per minute per 1.73 m
RESULTS: A total of 1584 participants underwent randomization - 793 were assigned to the finerenone group, and 791 to the placebo group. The mean (±SD) baseline eGFR was 46.8±16.2 ml per minute per 1.73 m
CONCLUSIONS: Among adults with CKD who did not have diabetes, finerenone led to a slower decrease in the eGFR than placebo over 32 months. (Funded by Bayer; FIND-CKD ClinicalTrials.gov number, NCT05047263.).
Volume
395
Issue
6
First Page
533
Last Page
545
ISSN
1533-4406
Published In/Presented At
Heerspink, H. J. L., Neuen, B. L., Agarwal, R., Cherney, D. Z. I., Lam, C. S. P., Tuttle, K. R., Wanner, C., Sarafidis, P., Jongs, N., Smeijer, J. D., Brinker, M., Rethemeier, N., Schloemer, P., Vesterinen, P., Goldsbury, D., Dizayee, S., Mares, J. W., Perkovic, V., & FIND-CKD Investigators (2026). Finerenone in Persons with Chronic Kidney Disease without Diabetes. The New England journal of medicine, 395(6), 533–545. https://doi.org/10.1056/NEJMoa2604625
Disciplines
Medicine and Health Sciences
PubMedID
42246672
Department(s)
Department of Medicine
Document Type
Article